Agios Pharmaceuticals Inc (NASDAQ:AGIO) – Investment analysts at Leerink Swann upped their Q1 2018 earnings estimates for Agios Pharmaceuticals in a research report issued to clients and investors on Thursday. Leerink Swann analyst M. Schmidt now forecasts that the biopharmaceutical company will earn ($1.61) per share for the quarter, up from their previous forecast of ($1.67). Leerink Swann also issued estimates for Agios Pharmaceuticals’ Q2 2018 earnings at ($1.44) EPS, Q3 2018 earnings at ($1.42) EPS, Q4 2018 earnings at ($1.34) EPS, FY2018 earnings at ($5.78) EPS, FY2019 earnings at ($4.41) EPS and FY2020 earnings at ($2.88) EPS.
A number of other brokerages have also recently issued reports on AGIO. BidaskClub cut shares of Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 16th. Cann reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, December 5th. Oppenheimer set a $83.00 price target on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, November 17th. Zacks Investment Research cut shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, January 15th. Finally, Royal Bank of Canada upped their price target on shares of Agios Pharmaceuticals to $91.00 and gave the stock an “outperform” rating in a research note on Thursday, January 18th. They noted that the move was a valuation call. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $85.50.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative net margin of 731.60% and a negative return on equity of 76.67%. The business had revenue of $9.80 million for the quarter, compared to the consensus estimate of $12.65 million. During the same quarter last year, the firm posted ($1.34) EPS. The business’s quarterly revenue was down 56.7% on a year-over-year basis.
Large investors have recently made changes to their positions in the stock. Royal Bank of Canada grew its stake in shares of Agios Pharmaceuticals by 40.8% during the 2nd quarter. Royal Bank of Canada now owns 9,131 shares of the biopharmaceutical company’s stock valued at $470,000 after acquiring an additional 2,648 shares during the period. Ameriprise Financial Inc. grew its stake in shares of Agios Pharmaceuticals by 21.9% during the 2nd quarter. Ameriprise Financial Inc. now owns 49,994 shares of the biopharmaceutical company’s stock valued at $2,572,000 after acquiring an additional 8,965 shares during the period. Northern Trust Corp grew its stake in shares of Agios Pharmaceuticals by 31.3% during the 2nd quarter. Northern Trust Corp now owns 232,802 shares of the biopharmaceutical company’s stock valued at $11,977,000 after acquiring an additional 55,560 shares during the period. Alps Advisors Inc. grew its stake in shares of Agios Pharmaceuticals by 9.1% during the 3rd quarter. Alps Advisors Inc. now owns 47,473 shares of the biopharmaceutical company’s stock valued at $3,169,000 after acquiring an additional 3,962 shares during the period. Finally, Brown Advisory Inc. grew its stake in shares of Agios Pharmaceuticals by 8.5% during the 3rd quarter. Brown Advisory Inc. now owns 291,139 shares of the biopharmaceutical company’s stock valued at $19,433,000 after acquiring an additional 22,736 shares during the period. Institutional investors own 84.04% of the company’s stock.
In other news, Director Lewis Clayton Jr. Cantley sold 3,838 shares of the company’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $59.37, for a total transaction of $227,862.06. Following the completion of the sale, the director now owns 80,851 shares of the company’s stock, valued at approximately $4,800,123.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Corp /De/ Celgene purchased 851,154 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, January 23rd. The shares were acquired at an average cost of $67.00 per share, with a total value of $57,027,318.00. Following the transaction, the insider now directly owns 1,374,599 shares in the company, valued at $92,098,133. The disclosure for this purchase can be found here. In the last three months, insiders sold 183,114 shares of company stock valued at $13,866,025. 5.43% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: “Leerink Swann Equities Analysts Boost Earnings Estimates for Agios Pharmaceuticals Inc (AGIO)” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2018/02/20/leerink-swann-equities-analysts-boost-earnings-estimates-for-agios-pharmaceuticals-inc-agio.html.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.